StockWatch
·
Healthcare Service Provider
Board Meeting23 Jul 2026, 03:43 pm

Thyrocare Q1 consolidated PAT up 34% YoY to ₹51 Cr on 24% revenue growth, margins expand

AI Summary

Thyrocare Technologies opened FY27 with a broad-based beat: consolidated revenue from operations rose 24.3% YoY to ₹240.02 Cr and profit for the period grew 34.1% to ₹51.33 Cr (owners' share ₹52.19 Cr), with net margin firming to ~21.4% from 19.4% a year ago. The print runs comfortably ahead of the 'mid- to high-teens' revenue growth management guided on the Q4 concall and the 15–22% FY27 PAT growth analysts were modelling, and confirms the confident, volume-led tone (75% volume / 25% mix, no price hikes) set on that call. Standalone tells the same story — revenue +26.1% to ₹225.66 Cr, PAT +39.2% to ₹50.17 Cr — so there is no divergence between the two bases. The engine is the core diagnostic testing business: segment revenue rose 26.9% YoY to ₹226.21 Cr and segment profit jumped ~38% to ₹61.90 Cr, driving the operating-margin expansion (OPM ~32.2% vs 29.9% YoY). Imaging remains the soft spot — revenue slipped to ₹13.48 Cr from ₹14.04 Cr and contributed a thin ₹1.26 Cr result. Against the prior quarter the picture is a sequential slowdown rather than acceleration: revenue is up only 7.2% and PAT up 5.4% QoQ, and headline OPM eased from Q4's 33.5%, consistent with management's stated intent to reinvest operating leverage back into growth rather than let it drop to margin, keeping normalized EBITDA around 34%. The quarter also carried a cluster of governance actions: Price Waterhouse Chartered Accountants LLP reviewed these results as the newly appointed statutory auditor (per the 30 June appointment), EY was re-appointed internal auditor for FY27, and the board had earlier set a 23 June record date for the FY26 final dividend. One drag to watch is the subsidiary layer — unreviewed subsidiaries posted a ₹0.84 Cr comprehensive loss and non-controlling interest turned negative (₹0.86 Cr), which is why group profit for the period sits below the owners' share. Management's promised specialty-diagnostics foray (genomics, allergy) is not yet visible as a separate driver in this print.

Key Highlights

  • Consolidated revenue from operations ₹240.02 Cr, up 24.3% YoY (₹193.03 Cr) and 7.2% QoQ (₹223.95 Cr)
  • Consolidated profit for the period ₹51.33 Cr, up 34.1% YoY and 5.4% QoQ; owners' share ₹52.19 Cr; EPS ₹3.23 (basic, not annualised)
  • Net margin expanded to ~21.4% from 19.4% YoY; operating margin ~32.2% vs 29.9% YoY but below Q4's 33.5%
  • Diagnostic Testing drove the beat — segment revenue ₹226.21 Cr (+26.9% YoY), segment profit ₹61.90 Cr (~+38%); Imaging weak at ₹13.48 Cr revenue
  • Standalone revenue ₹225.66 Cr (+26.1% YoY), PAT ₹50.17 Cr (+39.2% YoY) — no divergence from consolidated
  • No exceptional items this quarter; raw and adjusted YoY growth are the same
  • Governance: Price Waterhouse (new statutory auditor) reviewed results, EY re-appointed internal auditor for FY27; subsidiaries booked ₹0.84 Cr comprehensive loss, NCI negative ₹0.86 Cr